BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haack A, Aragão GG, Novaes MRCG. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases. World J Gastroenterol 2013; 19(46): 8552-8561 [PMID: 24379572 DOI: 10.3748/wjg.v19.i46.8552] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Silva Filho LVRF, Castaños C, Ruíz HH. Cystic fibrosis in Latin America—Improving the awareness. Journal of Cystic Fibrosis 2016;15:791-3. [DOI: 10.1016/j.jcf.2016.05.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
2 Shaw E, Wuest WM. Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients. RSC Med Chem 2020;11:358-69. [PMID: 33479641 DOI: 10.1039/c9md00566h] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Chu Y, Shuai J, Huang K, Liu J, Lv W, Li B. Analysis of Clinical Manifestations, Imaging Features, and Gene Mutation Characteristics of 6 Children with Cystic Fibrosis in China. Evid Based Complement Alternat Med 2021;2021:7254391. [PMID: 34765005 DOI: 10.1155/2021/7254391] [Reference Citation Analysis]
4 Lemoine C, Lokar J, Mccolley SA, Alonso EM, Superina R. Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant. Journal of Pediatric Surgery 2019;54:1076-82. [DOI: 10.1016/j.jpedsurg.2019.01.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
5 Sampaziotis F, de Brito MC, Madrigal P, Bertero A, Saeb-Parsy K, Soares FAC, Schrumpf E, Melum E, Karlsen TH, Bradley JA, Gelson WT, Davies S, Baker A, Kaser A, Alexander GJ, Hannan NRF, Vallier L. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol. 2015;33:845-852. [PMID: 26167629 DOI: 10.1038/nbt.3275] [Cited by in Crossref: 210] [Cited by in F6Publishing: 194] [Article Influence: 30.0] [Reference Citation Analysis]
6 Shen Y, Liu J, Zhong L, Mogayzel PJ, Zeitlin PL, Sosnay PR, Zhao S. Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis in Chinese Children. J Pediatr. 2016;171:269-76.e1. [PMID: 26826884 DOI: 10.1016/j.jpeds.2015.12.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
7 Ramadan S, Tammam SN, Shetab Boushehri MA, Breitinger H, Breitinger U, Mansour S, Lamprecht A. Liposomal delivery of functional transmembrane ion channels into the cell membranes of target cells; a potential approach for the treatment of channelopathies. International Journal of Biological Macromolecules 2020;153:1080-9. [DOI: 10.1016/j.ijbiomac.2019.10.238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Shi R, Wang X, Lu X, Zhu Z, Xu Q, Wang H, Song L, Zhu C. A systematic review of the clinical and genetic characteristics of Chinese patients with cystic fibrosis. Pediatr Pulmonol 2020;55:3005-11. [DOI: 10.1002/ppul.24980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhang D, Li S, Wang N, Tan HY, Zhang Z, Feng Y. The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases. Front Microbiol 2020;11:301. [PMID: 32158441 DOI: 10.3389/fmicb.2020.00301] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 33.0] [Reference Citation Analysis]
10 Lee LY, Hew GSY, Mehta M, Shukla SD, Satija S, Khurana N, Anand K, Dureja H, Singh SK, Mishra V, Singh PK, Gulati M, Prasher P, Aljabali AAA, Tambuwala MM, Thangavelu L, Panneerselvam J, Gupta G, Zacconi FC, Shastri M, Jha NK, Xenaki D, MacLoughlin R, Oliver BG, Chellappan DK, Dua K. Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities. Life Sci 2021;267:118973. [PMID: 33400932 DOI: 10.1016/j.lfs.2020.118973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Pallagi P, Hegyi P, Rakonczay Z. The Physiology and Pathophysiology of Pancreatic Ductal Secretion: The Background for Clinicians. Pancreas 2015;44:1211-33. [DOI: 10.1097/mpa.0000000000000421] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
12 Burke A, Smith D, Coulter C, Bell SC, Thomson R, Roberts JA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. Clin Pharmacokinet 2021. [PMID: 33982266 DOI: 10.1007/s40262-021-01010-4] [Reference Citation Analysis]
13 Bacci G, Rossi A, Armanini F, Cangioli L, De Fino I, Segata N, Mengoni A, Bragonzi A, Bevivino A. Lung and Gut Microbiota Changes Associated with Pseudomonas aeruginosa Infection in Mouse Models of Cystic Fibrosis. Int J Mol Sci 2021;22:12169. [PMID: 34830048 DOI: 10.3390/ijms222212169] [Reference Citation Analysis]
14 Giuffrida G, Campennì A, Cannavò S, Ruggeri RM. Commentary: L-T4 Therapy in Enteric Malabsorptive Disorders. Front Endocrinol (Lausanne) 2021;12:696768. [PMID: 34248852 DOI: 10.3389/fendo.2021.696768] [Reference Citation Analysis]
15 Heidari Z, Daei M, Boozari M, Jamialahmadi T, Sahebkar A. Curcumin supplementation in pediatric patients: A systematic review of current clinical evidence. Phytother Res 2021. [PMID: 34904764 DOI: 10.1002/ptr.7350] [Reference Citation Analysis]